✦ LIBER ✦

Mo1213 Efficacy and Safety of NNC0142-0002, a Novel Human Monoclonal Antibody Targeting NKG2D: a Randomized, Double-Blind, Single-Dose Phase 2 Trial in Patients With Crohn's Disease

✍ Scribed by Allez, Matthieu; Petryka, Robert; Skolnick, Brett E.; Wisniewska-Jarosinska, Maria A.

Book ID: 122170880
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 189 KB
Volume: 146
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(14)62128-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

493 Safety Profile and Signal of Efficac

493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study

✍ Christien J. van der Woude; Pieter C. Stokkers; Ad A. van Bodegraven; Gert A. Va 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 87 KB

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

A Multicenter, Randomized, Double-Blind,

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial

✍ William J. Sandborn; Christopher Gasink; Long-Long Gao; Marion Blank; Jewel Joha 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 145 KB

A multicenter, randomized, placebo-contr

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes

✍ E. J. Rhee; W. Y. Lee; K. H. Yoon; S. J. Yoo; I. K. Lee; S. H. Baik; Y. K. Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 531 KB

Efficacy and safety of ustekinumab, a hu

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

✍ Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 295 KB

Efficacy and safety of itolizumab, a nov

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

✍ Krupashankar, D.S.; Dogra, Sunil; Kura, Mahendra; Saraswat, Abir; Budamakuntla, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 694 KB